Avior Wealth Management’s Immuneering IMRX Stock Holding History

Avior Wealth Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4	Closed	-$11	–	2966
2024 Q1	$11	Buy	+4	New	+$22	﹤0.01%	3761

Other funds holding IMRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Avior Wealth Management's IMRX Position: Q2 2024 in Review

Avior Wealth Management sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 4 shares — an estimated $11 sold.

Avior Wealth Management first reported a position in IMRX in Q1 2024 and held it in 1 quarter. The position peaked at $11 in Q1 2024. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

Avior Wealth Management reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
Avior Wealth Management sold 4 Immuneering shares in Q2 2024, an estimated $11.
Avior Wealth Management first reported a position in Immuneering in Q1 2024 and held it in 1 quarter.
Avior Wealth Management's Immuneering position peaked at $11 in Q1 2024.
59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.